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ABSTRACT
Background: Biologicals are the cornerstone for
many treatment algorithms in inflammatory arthritis.
While tumour necrosis factor (TNF) inhibitors may
achieve important responses in ∼50% of patients with
rheumatoid arthritis (RA) and spondyloarthritis (SpA),
a significant fraction of patients are partial or non-
responders. We hypothesised that in vivo assessment
of TNF by scintigraphy with 99mTc-radiolabelled
certolizumab pegol (CZP) might lead to a more
‘evidence-based biological therapy’.
Objectives: Our goal was to perform a proof-of-
concept study of in vivo detection of TNF by
immunoscintigraphy of a radiolabelled TNF inhibitor in
RA and SpA, and correlate this with clinical, imaging
findings and therapeutic outcome.
Methods: CZP was conjugated with succinimidyl-6-
hydrazino-nicotinamide and subsequently radiolabelled
with Tc99m. Whole body and static images of hands,
feet and sacroiliac joints of 20 patients (5 RA; 15
SpA) were acquired at 3 time points.
Immunoscintigraphic findings were scored
semiquantitatively. Subsequently, all patients were
treated with CZP.
Results: In peripheral joints, clinically affected joints
or abnormal ultrasound findings were observed more
frequently (p<0.001) in the scintigraphic-positive
group. In patients with axial SpA, bone marrow
edema on MRI was detected more frequently
(p<0.001) in quadrants with tracer uptake. At the
patient level, the odds of a joint remaining tender
despite 24 weeks of CZP treatment was significantly
smaller in joints with clear tracer uptake as compared
with those with no uptake (OR=0.42, p=0.04).
Conclusions: Immunoscintigraphy with radiolabelled
CZP demonstrated both axial and peripheral
inflammation, and displayed good correlation with
clinical features, conventional imaging and therapy
response.
Trial registration number: NCT01590966; Results.
INTRODUCTION
Rheumatoid arthritis (RA) and spondyloar-
thritis (SpA) are both chronic inﬂammatory
joint diseases, with a combined prevalence
close to 2%. If untreated, persistent inﬂam-
mation may lead to functional disability, pro-
gressive structural damage and potentially to
also a number of extra-articular manifesta-
tions or comorbidities.1 2 Currently, the
aetiology is unknown, but a combination of
predisposing genetic factors, and person-
related or environmental factors (age,
gender, infectious agents, smoking, dietary
factors) is suspected to play a role in disease
Key messages
▸ Typical joint involvement patterns in peripheral
and axial disease were detected by using a
immunoscintigraphic procedure with radiola-
belled certolizumab pegol (CZP): polyarticular
pattern in rheumatoid arthritis, distal interpha-
langeal joint (DIP) involvement and dactylitis in
psoriatic arthritis, and enthesitis and sacroiliitis
in spondyloarthritis (SpA).
▸ A strong relationship with clinical involvement
and immunoscintigraphic uptake was observed;
tender or swollen joints or abnormal ultrasound
findings were significantly more prevalent when
scintigraphy was positive.
▸ In patients with axial SpA, bone marrow edema
on MRI was observed more frequently in quad-
rants that also showed uptake of the radiola-
belled CZP.
▸ A marked relationship with therapy response
was observed: the odds of a joint remaining
tender despite 24 weeks of CZP treatment was
significantly smaller in joints with clear tracer
uptake as compared to those without.
Carron P, et al. RMD Open 2016;2:e000265. doi:10.1136/rmdopen-2016-000265 1
Imaging
group.bmj.com on June 30, 2016 - Published by http://rmdopen.bmj.com/Downloaded from 
pathogenesis.3 4 Treatment strategies for SpA and RA
have changed dramatically over the last decade mainly
as a consequence of our growing knowledge of the
pathogenetic role of proinﬂammatory cytokines, such as
tumour necrosis factor α (TNF-α).5 6
Immunohistological studies demonstrated the pre-
sence of TNF-α and its receptors in inﬂamed tissues of
peripheral joints and/or sacroiliac joints (SIJs).7 The
introduction of ‘biological agents’ targeting TNF-α, with
either monoclonal antibodies (including Fab fragments)
or receptor-fusion proteins, has revolutionised our thera-
peutic armamentarium. Treatments neutralising TNF-α
have the longest track record in RA and SpA; currently
four monoclonal antibodies (adalimumab, certolizumab,
golimumab, inﬂiximab) and one receptor-fusion protein
(etanercept) are available.8 Certolizumab pegol (CZP;
UCB Celltech, Slough, Berkshire, UK) is an engineered
humanised monoclonal antibody Fc-free Fab′ fragment
with speciﬁcity for human TNF-α, manufactured in
Escherichia coli. The antibody fragment is subsequently
puriﬁed and conjugated with high molecular weight
polyethylene glycol (PEG; 40 kDa). CZP is approved
worldwide for adult patients with moderate-to-severe
active RA, ankylosing spondylitis (AS) and psoriatic
arthritis;9–11 moreover, the drug also received marketing
authorisation in Europe for the indication of non-
radiographic axial SpA (axSpA).12 In addition to RA,
CZP has demonstrated a positive beneﬁt risk in Crohn’s
disease and psoriasis.13 14
In clinical trials for RA and SpA, ∼50% of patients
achieve a clinically important response such as an
American College of Rheumatology (ACR) 50% response
rate or the Assessment of SpondyloArthritis international
Society (ASAS) 40% response rate.9 11 15–22 Despite an
overall impressive improvement in clinical signs and
symptoms when a TNF-blocking agent is administered,
there is still a signiﬁcant proportion of patients who do
not reach a relevant response (primary non-responder),
have insufﬁcient improvement, or who lose an initial
good response over time (secondary non-responder).
This may be due to lower levels of TNF-α expression at
the site of inﬂammation as it is known that there may be
a large interindividual and intraindividual variability in
these levels,23 or to the fact that the disease is in fact pre-
dominantly driven by other proinﬂammatory cytokines.
In an era of evidence-based medicine, it is disappointing
to realise that treatment decisions or strategies, even for
expensive biological agents, are driven by patient-
reported outcomes, the difﬁcult to standardise clinical
examinations ( joint counts), rather aspeciﬁc laboratory
parameters (elevated C reactive protein (CRP)) or ques-
tionable imaging cut-offs (erosions, sacroiliitis grade 2 by
modiﬁed New York criteria for AS). An accurate way of
predicting a relevant clinical response to a certain tar-
geted treatment would allow for a better patient selec-
tion. Molecular imaging studies aiming at selectively
visualising TNF-α (or another suspected culprit cytokine)
in vivo at the site of clinical inﬂammation could be an
attractive alternative to other less speciﬁc and/or invasive
techniques such as bone scintigrapy with 99mTc-labelled
diphosphonates or synovial biopsies taken by arthro-
scopic procedures. This more rational approach of deter-
mining the most appropriate biological treatment for an
individual patient may also have relevant consequences
for the cost-efﬁcacy of our currently available biological
drugs, and even have an impact on the design of future
clinical trials with targeted therapies. Therefore, we per-
formed a proof-of-concept study to explore the possibility
of visualising TNF-driven disease in patients with active
RA and SpA using scintigraphy with Tc99m-labelled CZP
as tracer, and to correlate the anti-TNF bound tracer with
the localisation of active clinical inﬂammation.
PATIENTS AND METHODS
Patients
The study was approved by the Medical Ethics
Committee of the Ghent University Hospital, and each
patient gave written informed consent. The study was
conducted in compliance with International Conference
on Harmonisation Good Clinical Practice guidelines and
the Declaration of Helsinki. (EudraCT number:
2009-017998-37).
We included 20 adult (18–70 years) patients with RA
(n=5), peripheral SpA (pSpA; n=6) or axSpA (n=9).
Patients were recruited from the Rheumatology
Outpatient Clinic of the University of Ghent, Belgium,
from November 2012 until November 2013.
All patients with RA fulﬁlled both the ACR revised
criteria for the diagnosis of RA24 and the 2010 ACR/
European League Against Rheumatism (EULAR) clas-
siﬁcation criteria,25 and all patients with SpA fulﬁlled
the current ASAS classiﬁcation criteria for axSpA or
pSpA.26 27 Patients with RA fulﬁlled Belgian reimbur-
sement criteria for the initiation of anti-TNF agents
(including failure of at least two disease-modifying
antirheumatic drugs, one of these being methotrexate)
and had active disease Disease Acitivity Score in 28
joints (DAS28≥3.7) with at least ﬁve swollen joints at
screening. Patients with pSpA had active arthritis, dac-
tylitis or enthesitis at screening despite treatment with
an adequate stable dose of sulfasalazine or methotrex-
ate for at least 3 months, or a stable, full dose of non-
steroidal anti-inﬂammatory drugs (NSAIDs) for at least
4 weeks. Patients with axSpA were required to still have
active disease (despite a stable, full dose of NSAIDs for
at least 4 weeks), deﬁned as a Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) ≥4 (0–10)
and active inﬂammatory lesions on MRI of the SIJs
(according to the deﬁnition of a positive MRI pro-
posed by the ASAS consortium) or radiographic sacroi-
liitis according to the modiﬁed New York criteria.26
Prior treatment with any biological treatment was an
exclusion criterion. All patients were screened for
latent tuberculosis by means of a tuberculin skin test
and chest X-ray.
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Clinical and laboratory assessments
Patients were evaluated through screening at baseline
(prior to the CZP scintigraphy), prior to initiation of
CZP, and at weeks 12 and 24 after start of CZP.
Evaluations were performed by the same rheumatologist
(PC) and consisted of a full rheumatological examina-
tion, including a 66/68 joint count, enthesitis and dacty-
litis assessments as well as an evaluation of axial
metrology. At all visits, a number of patient-reported out-
comes was assessed, including patient global assessment
(PGA) of disease activity, PGA of pain and Short Form
(SF)-36 for all patients, BASDAI and Bath Ankylosing
Spondylitis Functional Index (BASFI) for patients with
axSpA, and the Health Assessment Questionnaire
(HAQ) for patients with RA. During the screening 12
and 24 weeks after treatment, routine blood samples
were taken to assess potential toxicity of CZP treatment,
and determine erythrocyte sedimentation rate (normal
level <20 mm/hour) and level of CRP (normal level
<5 mg/L). This allowed for the calculation of validated
composite disease activity scores such as the DAS28 for
RA, and the Ankylosing Spondylitis Disease Activity
Score (ASDAS) for patients with SpA.
Imaging assessments
Ultrasound examination
Ultrasound (US) evaluation was performed at baseline
and after 12 weeks treatment with CZP in patients with
RA and pSpA. Systematic multiplanar grey scale (GS)
and power Doppler (PD) examinations were carried out
with an ESAOTE MyLab60 using multifrequency linear
transducers (6–18 MHz). PD imaging was performed by
selecting a region of interest that included the bony
margins, articular space and a variable view of surround-
ing tissues (depending on the joint size). PD variables
were adjusted to the lowest permissible pulse repetition
frequency (PRF) to maximise sensitivity. This setting
resulted in a PRF between 500 and 1000 Hz depending
on the joint scanned. Low wall ﬁlters were used. Colour
gain was set just below the level at which colour noise
appeared on the underlying bone (no ﬂow should be
visualised at the bony surface). We evaluated both wrists,
ankles and subtalar joints, as well as all metacarpopha-
langeal (MCP) and metatarsophalangeal joints. Synovitis
and tenosynovitis were assessed according to the EULAR
criteria28 and the OMERACT deﬁnition.29 Synovitis and
synovial and tenosynovial vascularity were scored semi-
quantitatively (grade 0–3) by PD US according to
Szkudlarek et al.30 Synovitis (effusion and synovial hyper-
trophy combined) in GS US was analysed semiquantita-
tively as described by Scheel et al.31 Tenosynovitis in GS
US was registered as being absent (0) or present (1).
MRI
All patients with axSpA and one patient with pSpA
underwent MRI of the SIJs. Images were obtained on a
1.5 T MRI unit (Avanto/Symphony, Siemens Medical,
Erlangen, Germany). The SIJs were imaged in a body
ﬂexed array coil (Siemens Medical, Erlangen,
Germany). The sequence protocol included semicoronal
(along long axis of the sacral bone) T1-weighted turbo
spin echo (slice thickness (ST) 3 mm; repetition time/
echo time (TR/TE) 595/20 ms), semicoronal short tau
inversion recovery (STIR) (ST 3 mm; TR/TE/inversion
time (TI) 5030/67/150 ms) and axial STIR (ST 5 mm;
TR/TE/TI 7540/67/150 ms). Sacroiliitis on MRI was
scored positive or negative according to the deﬁnition
proposed by the ASAS consortium.26 Each SIJ was
divided into four quadrants and evaluated on eight
coronal 3 mm MRI slices. Bone marrow edema (BME)
was scored per quadrant as either absent or present (on
two consecutive slices), thus providing a total score
between 0 and 8. BME of the SIJs was also scored using
the Spondyloarthritis Research Consortium of Canada
(SPARCC) scoring system by certiﬁed readers for the
SPARCC scoring system.32 The presence of an intense
signal (comparable to blood vessels) or depth ≥1 cm
anywhere within each SIJ of the six slices is given an
additional score (0=absent/1=present). Since in our
centre 3 mm slices are used, eight slices were evaluated
and converted to a maximum score of 72. MRI of the
SIJs was performed within the week before the immu-
noscintigraphy was obtained.
Scintigraphic assessments
Radiolabelling procedure of CZP
Lyophylised CZP was reconstituted with water for injec-
tion, ﬁltered and dialysed, and subsequently incubated
with succinimidyl-6-hydrazino-nicotinamide (S-HYNIC,
ABX GmbH, Radeberg, Germany). After removal of the
unreacted S-HYNIC, a bifunctional crosslinker, the solu-
tion was diluted with acetate buffer to a pH of 5 and ﬁl-
tered through a 0.22 µm membrane ﬁlter. Solutions of
1.25 mg S-HYNIC CZP were dispensed in 1.0 mL glass
vials stored at −80°C.
For the radiolabelling procedure, a co-ligand kit con-
sisting of a tin(II) sulfate (4.66 mM, Sigma Aldrich,
Steinheim, Germany) and tricine (55.81 mM, Sigma
Aldrich) diluted solution (50 µL) was added to the
S-HYNIC CZP vial. Subsequently, 925 MBq (±10%)
freshly eluated Tc99m pertechnetate was added to this
vial. This was incubated for 15 min at room temperature.
Finally, physiological saline was added to dilute the
radiopharmaceutical formulation in a total volume of
3 mL. All handling was performed under aseptic condi-
tions. Quality control was carried out by instant thin
layer chromatography with Silica gel (SilG) as stationary
phase and 0.9% NaCl solution as mobile phase. For clin-
ical use, the radiochemical yield needed to exceed 90%.
Scintigraphic procedure
Patients were injected intravenously with ∼740 MBq
Tc99m-labelled CZP (10.6 MBq/kg). All patients were
scanned on the same double-headed γ-camera
(BrightView, Philips Healthcare, Best, The Netherlands).
Whole body (WB) images (15 cm/min scan speed,
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matrix size 1024×512, pixel size 2.80 mm) were per-
formed immediately following administration, at 1, 4–6
and 24 hours postinjection. A standard activity of
∼5 MBq Tc99m in an unshielded syringe was always in
the ﬁeld of view for quantiﬁcation purposes. Static
images (5 min, matrix size 256×256, pixel size 2.33 mm)
of hands and feet were acquired immediately following
the ﬁrst WB scan which was started within a couple of
minutes postinjection, at 4–6 and 24 hours postinjection.
A single photon emission tomography (SPECT) was
acquired from the axial skeleton. In selected cases, a
SPECT/CT was performed to depict in detail the
involved joints.
To assess the tracer accumulation in the peripheral
joints, each joint was scored semiquantitatively by using
the following scoring system: score 0=no tracer uptake,
score 1=faint uptake of the tracer and score 2=clear
uptake of the tracer. The same score was applied to
every quadrant of the SIJs in patients with axSpA. The
scintigraphic result was deﬁned as positive if there was
faint or clear tracer uptake 4–6 hours postinjection. As
the scintigraphic images do not provide anatomic
details, fusion of the MRI with the nuclear image was
performed to allow scoring of the tracer uptake per
quadrant. For each individual scan, a background region
of interest (ROI) was deﬁned within the ﬁeld of view,
for example, left supraclavicular region on WB, right
forearm on static images of the wrists and hands, and
right distal tibia for the static images depicting the
ankles and feet. These results were compared with the
ﬁndings from clinical examination of each assessable
joint. The nuclear medicine physician reading the
immunoscans, and the clinician performing the clinical
examination were blinded to each other’s observations.
Statistical analysis
Data were analysed using SAS V.9.3 (SAS Institute Inc,
Cary, North Carolina, USA). Both a joint-based and
patient-based analysis were done. In the joint-based ana-
lysis, each individual joint contributes an observation,
but clustering of the joints within the patient was taken
into account in the statistical analysis. For this analysis a
scintigraphic score corresponding to either faint or clear
tracer uptake 4–6 hours postinjection was considered as
positive. To determine the relationship between the scin-
tigraphic variable and the (clinical or US) status of the
joint at baseline, a mixed logistic regression model with
patient as random effect was used. For the predictive
value of the scintigraphic variable on the status of the
joint 12 and 24 weeks after treatment, the data set is
reduced to only those joints that were tender and/or
swollen at baseline according to the variable assessed in
the analysis. A mixed logistic regression model with
patient as random effect is used on this reduced data
set. The results of the logistic regression model are sum-
marised in terms of the OR and percentage of tender
and/or swollen joints in the positive and negative scinti-
graphic group. In the patient-based analysis summary
statistics at the patient level was used. In this analysis the
sum of the semiquantitative scintigraphic scores was
used: for patients with RA, the scores of wrists, MCP and
proximal interphalangeal joint (PIP) joints were used
whereas in pSpA, the scores of the hand distal interpha-
langeal joint (DIP) joints were added; in patients with
axSpA, the sum scores of the quadrants of the SIJs was
used. To assess the predictive value of the scintigraphic
variable at baseline on the clinical improvement at 12
and 24 weeks after treatment (measured by ASDAS for
patients with axSpA and pSpA; measured by DAS28 for
patients with RA), a linear regression model is used with
the scintigraphic scores included as a continuous vari-
able. The results are summarised in terms of the slope.
The slope describes the change in the respective clinical
score with a unit increase in the scintigraphic variable.
For all analyses p<0.05 was considered statistically
signiﬁcant.
RESULTS
Patients baseline and disease characteristics and clinical
response after 12 and 24 weeks treatment with CZP
Table 1 depicts the baseline characteristics and the clinical
response after 12 and 24 weeks of treatment with CZP. The
mean age±SD of patients with RA, pSpA and axSpA at
baseline was 56.2±10.1, 41.0±10.3 and 37.1±10.7 years with
a mean symptom duration of 13.1±15, 12.6±14.9 and 9
±6.7 years, respectively. The mean CRP level at baseline for
patients with RA, pSpA and axSpA was 10.9, 15.4 and
4.7 mg/L, respectively. In general, there was a clear
improvement of signs and symptoms in all patients treated
with CZP. Three of the ﬁve patients with RA had a good
EULAR DAS28 response, and two had a moderate EULAR
DAS28 response after 12 weeks treatment. At 24 weeks,
loss of response was observed in one patient with RA.
Three of the six patients with pSpA showed a major
ASDAS improvement after 12 weeks treatment while two
had a clinically important ASDAS improvement. One
patient with pSpA was a (primary) non-responder, and
one patient with pSpA lost response after 24 weeks treat-
ment. In the patients with axSpA group, two out of
nine had a major ASDAS response, and six patients had a
clinically important ASDAS response. Again, one patient
with axSpA was a primary non-responder and one patient
with axSpA lost response at 24 weeks treatment. The
scintigraphic procedure was well tolerated. No
procedure-related adverse events were observed.
Description of distinct scintigraphic patterns observed in
patients with RA and SpA
In most of the clinically involved joints of hands and
feet in patients with RA and pSpA, a tracer uptake was
immediately visualised within minutes following the
injection, probably due to vascular hyperaemia. At 4–
6 hours postinjection, more joints were showing an
enhanced uptake, with the more favourable
joint-to-background ratio allowing a good anatomical
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Table 1 The baseline characteristics of all patients and their clinical response after 12 and 24 weeks treatment with CZP
Baseline characteristics
Demographic
characteristics Disease characteristics After 12 weeks CZP After 24 weeks CZP
Age
(years)
Gender
(M/F)
Symptom
duration
(years)
Concomitant
sDMARDs
Concomitant
corticosteroids
Concomitant
NSAIDs
CRP
(mg/L)
ESR
(mm/hour)
DAS
28 ASDAS
CRP
(mg/L)
ESR
(mm/hour) DAS28 ASDAS
CRP
(mg/L)
ESR
(mm/hour) DAS28 ASDAS
RA (n=5)
68.8 F 38.7 MTX 10 mg Yes No 32 23 6.77 – 1.5 4 1.93 – 0.8 4 1.76 –
62.1 F 3.1 MTX 10 mg Yes No 8.6 11 6.33 – 13.3 13 4.79 – 9.1 16 3.29 –
57.2 M 1.5 MTX 15 mg Yes No 9.5 24 5.8 – 0.6 4 4.31 – 0.7 6 4.86 –
42.8 F 11.6 MTX 12.5 mg No No 3.9 15 4.62 – 2 12 2.16 – 3.7 11 2.24 –
50.3 F 10.8 No Yes No 0.6 8 3.89 – 0.6 10 2.31 – 0.6 10 3.87 –
pSpA (n=6)
45.9 M 17.3 MTX 15 mg No Yes 51.9 67 – 4.78 2.8 6 – 1.56 0.6 2 – 0.99
36.8 F 0.9 No No Yes 3.4 5 – 4.16 1.6 4 – 3.87 1.6 4 – 3.87
55.4 F 39.9 No No Yes 0.1 6 – 2.18 0.6 3 – 1.02 0.6 7 – 2.98
44.8 M 4.2 LEF No Yes 28.2 57 – 3.89 0.6 5 – 0.46 0.7 5 – 0.93
25.1 M 1.2 SSZ No Yes 3.5 6 – 3.64 0.6 1 – 1.38 0.6 2 – 0.88
37.8 M 12.2 No No No 5.1 14 – 2.35 0.6 3 – 0.38 0.6 5 – 0.56
nraxSpA (n=5)
26.7 F 4.4 No No Yes 9 8 – 3.05 2.7 3 – 1.65 0.7 2 – 1.61
42.4 M 5.2 No No Yes 2.5 5 – 2.94 0.7 2 – 2.22 0.6 1 – 2.91
45.8 M 19 No No Yes 4 11 – 2.67 0.6 3 – 0.73 0.6 3 – 0.68
44.5 M 3.5 No No Yes 6.3 4 – 3.38 3.9 5 – 1.58 4.2 7 – 3.25
35.2 F 19 No No Yes 4 5 – 4.07 6.2 8 – 2.59 5.7 11 – 2.18
AS (n=4)
29.2 M 4.6 No No Yes 8 15 – 4.27 4.1 8 – 1.66 1.3 1 – 1.14
27.2 M 12.3 No No Yes 1.1 1 – 3.28 4.2 2 – 1.32 0.6 2 – 0.63
26.3 M 1.6 No No Yes 3 4 – 2.31 0.6 2 – 0.63 0.6 2 – 0.44
56.4 M 11.4 No No Yes 4.6 6 – 3.4 1.3 2 – 1.2 2.1 5 – 1.52
axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C reactive protein; CZP, certolizumab pegol; DAS28, Disease Activity
Score in 28 joints; ESR, erythrocyte sedimentation rate; LEF, leflunomide; M/F, male/female; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; pSpA, peripheral
spondyloarthritis; RA, rheumatoid arthritis; sDMARDS, synthetic disease-modifying antirheumatic drugs; SSZ, sulfasalazine.
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discrimination of the various joints. In most joints, the
tracer accumulation persisted over time on the 24-hour
postinjection images. A typical polyarticular pattern of
hand and feet joints without DIP involvement was seen
in RA (ﬁgure 1A). In contrast, there was clear DIP invol-
vement seen in the hands of a patient with polyarticular
psoriatic arthritis (ﬁgure 1B). As a proof-of-concept,
selected patients with pathognomonic clinical features
were also scanned and in patients with pSpA with dactyli-
tis, a speciﬁc scintigraphic pattern was observed with
tracer uptake in the joints and the accompanying ﬂexor
tendon of the clinically involved digit of the hand or
foot (ﬁgure 1C). Clear tracer uptake was also noticed at
the enthesis of Achilles tendon and plantar fascia in
patients with SpA with clinical and US-conﬁrmed enthe-
sitis (ﬁgure 1D). Tracer uptake could also be detected
in the region of the SIJs in patients with axSpA with
active inﬂammatory lesions on MRI (ﬁgure 1E).
Relationship between scintigraphic results and status of
peripheral joints and SIJs at baseline
Results of the joint-based analysis are presented in
tables 2–4. First, using the clinical evaluation of all
peripheral joints in all patients as a reference, we compared
the percentage of tender and/or swollen joints to the scinti-
graphic result at baseline (tables 2 and 3). The percentage
clinically involved joints was signiﬁcantly higher (p<0.0001)
in the scintigraphy-positive as compared with the
scintigraphy-negative joints. In patients with RA and pSpA,
the baseline US GS and PD results were additionally com-
pared with the scintigraphic result (table 4). Also, the per-
centage of GS-positive and PD-positive joints was
signiﬁcantly higher (p<0.001) in the scintigraphy-positive as
compared with the scintigraphy-negative joints. Higher ORs
were observed for the swollen joint count and PD-positive
joints as compared with the tender joint count and
GS-positive joints. Finally, in patients with axSpA, the per-
centage of SIJ quadrants showing BME on MRI was signiﬁ-
cantly higher (p=0.001) in the scintigraphic-positive as
compared with the scintigraphic-negative joints (table 4).
Maksymowych et al32 graded a lesion as deep on MRI if
there is a homogeneous and unequivocal increase in signal
extending over a depth of at least 1 cm from the articular
surface; this type of lesion was observed in seven of the nine
patients with axSpA and in ﬁve out of these seven patients
with axSpA (71%), clear scintigraphic tracer uptake was
Figure 1 Distribution of Tc99m-radiolabelled certolizumab pegol in hands, feet and SIJs 4–5 hours postinjection. (A) A typical
polyarticular pattern of hand and feet joints without distal interphalangeal joint (DIP) involvement was seen in a patient with active
rheumatoid arthritis. (B) Distal interphalangeal joint uptake of the left second digit in a patient with polyarticular psoriatic arthritis. (C)
Tracer uptake in both the joints and the accompanying flexor tendon in a patient with clinically dactylitis of the fourth digit at the right
side. (D) SPECT-CT of the right foot in a patient with spondyloarthritis with enthesitis of the Achilles tendon. (E) Fusion of MRI and
SPECT image of the sacroiliac joints of a patient with axial spondyloarthritis. SPECT, single photon emission tomography.
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Table 4 The number and percentages of US grey scale and US power Doppler and MRI-positive joints at baseline as a function of the scintigraphic status at baseline
Scintigraphic negative Scintigraphic positive OR p Value
Patients with RA and pSpA
US assessment Normal US
findings
Abnormal US
findings
Normal US
findings
Abnormal US
findings
US grey scale 192 (90.6%) 20 (9.4%) 28 (37.8%) 46 (62.2%) 15.77 <0.001
US power Doppler 207 (97.6%) 5 (2.4%) 33 (44.6%) 41 (55.4%) 51.44 <0.001
Patients with axSpA
MRI assessments SIJs No BME BME No BME BME
BME per quadrant 34 (70.8%) 14 (29.2%) 7 (21.9%) 25 (78.1%) 8.67 <0.001
The OR refers to the odds of a joint being US grey scale and US power Doppler positive or MRI positive in the scintigraphic-positive as compared with the scintigraphic-negative group. For all
tests, p values <0.05 are considered to indicate statistical significance.
axSpa, axial spondyloarthritis; pSpA, peripheral spondyloarthritis; RA, rheumatoid arthritis; SIJs, sacroiliac joints; US, ultrasound.
Table 3 The number and percentages of swollen joints at baseline, and after 12 and 24 weeks of treatment as a function of the scintigraphic status at baseline
All patients
Scintigraphic negative Scintigraphic positive
OR p ValueNo swelling Swelling No swelling Swelling
Swollen joints at baseline 1059 (98.3%) 18 (1.7%) 104 (62.3%) 63 (37.7%) 36.85 <0.001
Not swollen anymore
at w12 or w24
Remains swollen
at w12 or w24
Not swollen anymore
at w12 or w24
Remains swollen
at w12 or w24
Swollen joints at w12 18 0 56 (88.9%) 7 (11.1%) * 0.339
Swollen joints at w24 18 0 58 (92.1%) 5 (7.9%) * 0.581
The OR refers to the odds of a joint being tender and/or swollen in the scintigraphic-positive as compared with the scintigraphic-negative group. For all tests, p values <0.05 are considered to
indicate statistical significance.
*ORs for swollen joint count could not be estimated due to the fact that one cell, that is, scintigraphic-negative symptom has frequency zero.
w12, week 12; w24, week 24.
Table 2 The number and percentages of tender joints at baseline, and after 12 and 24 weeks of treatment as a function of the scintigraphic status at baseline
Scintigraphic negative Scintigraphic positive
OR p ValueAll patients No tenderness Tenderness No tenderness Tenderness
Tender joints at baseline 1057 (91.8%) 95 (8.2%) 94 (56.3%) 73 (43.7%) 8.60 <0.001
Not tender anymore
at w12 or w24
Remains tender
at w12 or w24
Not tender anymore
at w12 or w24
Remains tender
at w12 or w24
Tender joints at w12 69 (72.6%) 26 (27.4%) 58 (79.5%) 15 (20.5%) 0.69 0.309
Tender joints at w24 65 (68.4%) 30 (31.6%) 64 (87.7%) 9 (12.3%) 0.30 0.004
w12, week 12; w24, week 24.
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observed in the same quadrant of the SIJs, where the
extended lesion was also located. Interestingly, in one
patients with AS with complete fusion of the SIJs (bilateral
grade 4 sacroiliitis on X-ray), who was suffering from periph-
eral arthritis (and hence was included in the pSpA part of
the study), there was an absence of BME of the SIJs on
MRI. In this patient we could also not detect tracer uptake
on scintigraphy. Although this is only a solitary case, it
might suggest that in vivo detection of TNF correlates with
active inﬂammatory lesions on MRI and not with structural
damage.
Relation scintigraphic results and status of the patient at
baseline
On a patient level, a linear regression model was ﬁtted
regressing the sum of the semiquantitative scintigraphic
scores on patient-reported outcomes (SF-36, PGA of
disease activity, PGA of pain) and relevant disease activ-
ity scores (DAS28 for RA, ASDAS for SpA). No signiﬁ-
cant linear relationship was found between the
scintigraphic sum score and patient-reported outcomes
or disease activity scores at baseline. Nevertheless, we
found a signiﬁcant relationship between the scinti-
graphic sum score of the SIJs and the SPARCC score
(p=0.010). Each unit increase in the SPARCC score cor-
responds to an increase of 0.4139 (SE=0.119) in the scin-
tigraphic sum score (ﬁgure 2).
Prediction of therapy response by scintigraphic result on
joint and patient level at weeks 12 and 24
Finally, the scintigraphic result was analysed as a potential
predictor of therapy response of the joint level and patient
level. At the joint level, we observed a signiﬁcant result for
the number of tender joints at week 24 (table 2): of all
tender joints that were positive on scintigraphy at baseline,
only 11.9% remained painful at week 24, compared with
26.5% in the scintigraphy-negative joints (OR=0.38;
p=0.030). Results for swollen joints are summarised in
table 3; no signiﬁcant correlation was found.
At the patient level, a linear regression model was
ﬁtted regressing the sum of the semiquantitative scinti-
graphic scores on the change in patient-reported out-
comes (SF-36, PGA of disease activity, PGA of pain),
physician global assessment and relevant disease activity
scores by inserting group as adjusting factor in the
model. For patients with RA, the difference in DAS28
between baseline and weeks 12 and 24 was used and
regressed on the scintigraphic sum score. For patients
with SpA, the difference in ASDAS between baseline
and weeks 12 and 24 was used and regressed on the scin-
tigraphic sum score. No signiﬁcant relationships were
found.
DISCUSSION
We performed a proof-of-concept study on patients with
RA and SpA to detect in vivo TNF-α-driven inﬂammation
by scintigraphy using radiolabelled CZP. We visualised in
most of the clinically involved joints a marked tracer
uptake within minutes following injection, suggesting
fast uptake into the inﬂamed tissue. The best results
were seen at 4–6 hours postinjection, but tracer uptake
was still observed on the 24 hours postinjection scan,
suggesting that uptake is not solely caused by a vasculari-
sation effect. We were able to visualise speciﬁc tracer
uptake patterns pathognomonic for the studied diseases.
Although similar results have been reported with
Figure 2 Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA,
pSpA and axSpA. ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; DAS28, Disease
Activity Score in 28 joints; pSpA, peripheral spondyloarthritis; RA, rheumatoid arthritis; SPARCC, the Spondyloarthritis Research
Consortium of Canada scoring system.
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radiolabelled adalimumab in patients with RA,33 34 this
is—to the best of our knowledge—the ﬁrst study to eval-
uate immunoscintigraphic patterns in patients with dif-
ferent subtypes of SpA by visualising enthesitis, dactylitis
and sacroiliitis.
Second, in patients with peripheral joint involvement,
we could establish a good correlation between the clini-
cal evaluation and conventional imaging of the indivi-
dual joints, and the tracer uptake on scintigraphy.
Interestingly, this correlation was strongest for more
objective signs of inﬂammation: higher ORs were
observed for the swollen joint count and PD-positive
joints as compared with the tender joint count and
GS-positive joints. At the patient level, no signiﬁcant cor-
relation was found between the scintigraphic sum score
and global disease activity scores or relevant patient-
reported outcomes. In patients with axSpA, the scinti-
graphic ﬁndings correlated well with BME on MRI
of the SIJs, which is the item that is required in the
ASAS deﬁnition of a positive MRI,35 and is one of the
anchors of the ASAS classiﬁcation criteria for axSpA.
Nevertheless, the interpretation of a ‘positive MRI’ in
the context of SpA remains difﬁcult, deﬁnitely when the
presence of BME is subtle or when there may be other
causes for the observed BME, such as mechanical stress.
As a consequence, there is still an unmet need to deter-
mine whether observed BME is caused by underlying
cytokine-driven inﬂammation in patients with axSpA. At
present, there is no agreement on a precise deﬁnition of
the minimum size (area) of BME which is necessary to
be deﬁned as ‘positive’. There is an impression that the
presence of so-called ‘deep’ BME lesions on MRI of the
SIJs, deﬁned as a homogeneous and unequivocal
increase in signal extending over at least 1 cm from the
articular surface on STIR images, would be more sugges-
tive of axSpA. In our study, taking only these extended
lesions on MRI of the SIJs into account, better correla-
tions between scintigraphy and MRI were found. Finally,
at the patient level, there was a signiﬁcant relation
between the scintigraphic sum score of the SIJs and the
SPARCC scoring system.
Third, we looked whether the baseline scintigraphic
detection of TNF could predict a therapeutic response
to CZP therapy after 12–24 weeks. We need to emphasise
that this study was not designed or powered to predict
therapy response by baseline scintigraphic results.
Nevertheless, we could demonstrate a signiﬁcant predic-
tive value of the immunoscintigraphy at the joint level
with regard to the tender joint count: tender joints with
uptake at baseline had a signiﬁcantly higher probability
of not being painful after 24 weeks of treatment. The
lack of predictive value for the other joint assessments,
as well as for the global disease activity scores at the
patient level, could probably be explained by the fact
that the study included only small numbers of patients
with heterogeneous inﬂammatory diseases. These preli-
minary ﬁndings are, however, interesting because a posi-
tive scintigraphic result might indicate that joint
tenderness at baseline is TNF-driven, and this result
could serve as a more objective measurement tool for
tender joints. Surprisingly, only two prospective cohort
studies in RA have assessed the use of imaging techni-
ques to predict response to anti-TNF therapy. Ellegaard
and colleagues measured US Doppler activity and clini-
cal parameters at baseline to predict which patients
would beneﬁt from treatment, assessed by treatment per-
sistence at 1 year. They identiﬁed US Doppler activity to
be the only baseline parameter able to predict treatment
persistence (p=0.024); baseline clinical measures,
including tender and swollen joint counts, CRP, DAS28,
and HAQ showed no signiﬁcant association.36 Elzinga
and colleagues used changes in positron emission tomo-
graphy (PET) uptake 2 weeks after treatment to predict
future treatment response, according to DAS28. A signif-
icant correlation was seen between the changes in PET
activity at 2 weeks, and DAS28 at 14 and 22 weeks after
treatment (r 0.62, p<0.05; r 0.65, p<0.01, respectively).37
In the past, only few attempts in molecular imaging
using radiolabelled monoclonal antibodies in rheumatic
diseases were made, and the earliest experiences and
clinical context are excellently summarised by Malviya
et al.38 Our study is the ﬁrst using a radiolabelling proce-
dure with CZP, a PEGylated Fab fragment directed
against TNF-α. One of the reasons for choosing CZP as a
tracer was the observation made in an animal model for
arthritis using bioﬂuorescence imaging: a greater ratio
of penetration and more prolonged duration of expo-
sure in inﬂamed versus normal tissue was described for
CZP compared with adalimumab and inﬂiximab. One
possible explanation could be the link with PEG in
CZP.39
We acknowledge that our study has several limitations,
both regarding the scintigraphic technique, as well as
concerning the type of patients that was studied. Barrera
et al33 published encouraging ﬁndings with radiolabelled
adalimumab in 10 patients with active RA. A subset of
patients underwent repeat imaging following administra-
tion of a therapeutic dose of cold antibody. Based on this
competition study, the authors suggested a partial speciﬁc
targeting of TNF-α by Tc99m-labelled adalimumab.
These ﬁndings were in agreement with Roimicher et al.34
We decided not to include a competition study and
prioritised to ﬁrst have an estimation of the radiation
burden before exposing volunteering patients twice.40
We also did not perform a second immunoscintigrapy
after 12 or 24 weeks of treatment in order to evaluate the
change in tracer uptake over time. We ﬁrst wanted to
establish a proof-of-concept with this new radiopharma-
ceutical before endorsing more complex follow-up scinti-
graphic procedures. Nevertheless, it was Conti et al41 who
showed a positive predictive role of 99mTc-inﬂiximab
scintigraphy in therapy decision-making for patients with
refractory monoarthritis who were given intra-articular
inﬂiximab treatment by comparing the pretherapy and
post-therapy target-to-background ratio from affected
joints.
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With regard to patient selection, this was obviously a
proof-of-concept study, which included only limited
numbers of patients with different inﬂammatory rheu-
matic diseases. We did not include a non-inﬂammatory
control group; as a consequence, we cannot exclude
that the observed tracer uptake could be an aspeciﬁc
phenomenon, although the good correlation with the
clinical evaluation and conventional imaging results
would argue against this. The low number of patients in
each disease subgroup evidently does not allow us to
make conclusions regarding prediction of clinical
response in case of a positive scintigraphy; nevertheless,
the ﬁnding that individual painful joints that were
scintigraphy-positive had a higher odds of becoming not
tender after treatment with certolizumab could be a pro-
mising ﬁnd. Indeed, since treat-to-target principles have
found their way in the daily management of patients
with RA,42 a high number of tender joints might be one
of the triggers to change the therapeutic strategy: infor-
mation as to whether the observed pain pattern is
related to in vivo expression of a culprit cytokine could
potentially avoid overtreatment with biologicals in indivi-
dual cases where pain is driven by other pathophysiologi-
cal mechanisms.
CONCLUSION
In conclusion, we demonstrated that it is safe and feasi-
ble to perform scintigraphy with radiolabelled CZP in
patients with different types of inﬂammatory arthritis,
whereby speciﬁc joint involvement patterns could be
recognised. Future research should conﬁrm these preli-
minary results, speciﬁcally with regard to the potential
to predict clinical response to a biological treatment tar-
geting TNF. If conﬁrmed, the technique could be a step
towards personalised medicine, where each patient
receives the right drug and the right intensity of treat-
ment for as long as needed; it could allow the selection
of patients for a speciﬁc therapy in a much more
rational way than the current ‘trial and error’ approach.
In particular, future studies should address if a prether-
apy scintigraphic approach with a radiopharmaceutical
targeting TNF identiﬁes the presence of the target cyto-
kine in the inﬂammatory lesion and if positive, whether
these patients with clear uptake of the anti-TNF tracer
would respond better to anti-TNF therapy as compared
with strategies targeting other inﬂammatory pathways.
This might be a crucial step in enhancing the safe and
cost-effective use of expensive biological treatment by
avoiding exposure of non-responders to treatments such
as anti-TNF therapy.
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